Florida is currently home to 3745 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Miami, Tampa, Jacksonville and Orlando. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
CBT-I vs. MBTI for Traumatic Brain Injury (TBI)-Related Insomnia and Post-Traumatic Stress Symptoms
Recruiting
This study is a prospective two-arm, single blind randomized controlled trial design to compare the clinical effectiveness of telemedicine-delivered, 6-session, standardized cognitive behavioral therapy for insomnia (CBT-I) and mindfulness-based treatment for insomnia (MBTI) in treating insomnia symptoms and ameliorating depressive symptoms in persons with mild to moderate TBI and comorbid Post-Traumatic Stress Symptoms (PTSS) and insomnia symptoms in a 360 patients. Participants will undergo as... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/19/2024
Locations: Intrepid Spirit Center - Eglin Air Force Base, Eglin Air Force Base, Florida
Conditions: Traumatic Brain Injury, Insomnia, Depression, Post-traumatic Stress, Sleep, Memory Impairment, Cognitive Behavioral Therapy, Concussion, Brain, Head Injury, Brain Injury Traumatic Mild
Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors
Recruiting
The goal of this clinical trial is to learn about HT-001 Topical Gel for treatment of EGFR inhibitor-induced skin toxicities. The main questions it aims to answer are: * Determine the therapeutic effect of HT-001 for treatment of patients who develop acneiform rash undergoing Epidermal Growth Factor inhibitor (EGFRI) therapy using the acneiform rash investigator's global assessment scale \[ARIGA\] * Evaluate the safety of HT-001 during treatment Participants will apply HT-001 Gel once per day... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/19/2024
Locations: University of Miami, Miami, Florida
Conditions: Acneiform Eruption Due to Chemical, Xerosis Cutis, Paronychia
Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)
Recruiting
The trial will evaluate efficacy, safety and tolerability of ianalumab compared to placebo, given as monthly subcutaneous (s.c.) injection on top of standard-of-care (SoC) treatment in participants with active systemic lupus erythematosus (SLE).
Gender:
ALL
Ages:
Between 12 years and 100 years
Trial Updated:
12/19/2024
Locations: Homestead Assoc In Research Inc, Homestead, Florida
Conditions: Systemic Lupus Erythematosus
Pathological Myeloid Activation After Sepsis and Trauma
Recruiting
The goal of this observational study is to better understand what happens to circulating blood after a patient experiences severe trauma injury. The main questions it aims to answer are: Is severe human trauma associated with specific patterns of development in the hematopoietic stem cells of these patients? and Does the initial severe trauma injury create immunosuppression and increase risk of in-hospital sepsis? Participants in study will give blood samples and a waste sample of bone marrow at... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
12/19/2024
Locations: UF Health at Shands Hospital, Gainesville, Florida
Conditions: Trauma Injury, Sepsis, Immunosuppression, Chronic Critical Illness
CGM and Lifestyle Changes in Patients with Impaired Glucose Tolerance
Recruiting
The incidence of type 2 diabetes (T2D) in children is increasing, paralleling the rising incidence of obesity. Preventing children and adolescents from developing T2D is critical. The health benefits of lifestyle modifications are well documented in this population, but success rates are low. Obesity in children and adolescents increases the risk of not only T2D but other complications as well, such as hypertension, dyslipidemias and more. The investigators hypothesize that having real-time gluc... Read More
Gender:
ALL
Ages:
Between 10 years and 16 years
Trial Updated:
12/19/2024
Locations: Nemours Children's Clinic, Jacksonville, Florida
Conditions: Impaired Glucose Tolerance
An Efficacy and Safety Study of Basimglurant (NOE-101) in Patients with Trigeminal Neuralgia.
Recruiting
Trigeminal neuralgia (TN), also called "tic douloureux", is the most common form of craniofacial neuropathic pain and is considered the cause of one of the most painful afflictions known in medical practice. This study is designed to evaluate the efficacy and safety of 1.5mg - 3.5mg basimglurant in adults with TN.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
12/19/2024
Locations: University of South Florida (Site #: 1002), Tampa, Florida
Conditions: Trigeminal Neuralgia
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
Recruiting
This randomized phase II trial studies how well chemotherapy before surgery and radiation therapy works compared to surgery and radiation therapy alone in treating patients with nasal and paranasal sinus cancer that can be removed by surgery. Drugs used in chemotherapy, such as docetaxel, cisplatin, and carboplatin work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/19/2024
Locations: UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida
Conditions: Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7
Adolescent Outcomes of Post-operative Opioid EXposure
Recruiting
The goal of this observational study is to examine the factors associated with the transition from medical exposure to opioids with "signposts" of future opioid use disorder among adolescent surgical patients. The main question aims to identify factors (moderators, mediators, and covariates) associated with risk factors for opioid use disorder (ROUD) in the 12 months following major surgery with opioid exposure among adolescents aged 12-17. Participants will be asked to complete electronic surve... Read More
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
12/18/2024
Locations: Johns Hopkins All Children's Hospital, St. Petersburg, Florida
Conditions: Opioid Use Disorder, Pain, Chronic
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Recruiting
The purpose of this study is to establish a safe and tolerable dose of BMS-986393 in combinations with alnuctamab, mezigdomide, and iberdomide in participants with relapsed and/or refractory multiple myeloma (RRMM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/18/2024
Locations: Local Institution - 0005, Jacksonville, Florida
Conditions: Multiple Myeloma
Efficacy in Controlling Myopia in Young Children Using a Novel Spectacle Lens
Recruiting
This is a conventional efficacy trial to validate the results from previous clinical trials for younger children; the 12-month efficacy results will be used to predict the 3-year treatment efficacy. This is a randomized, controlled (1:1), multisite, subject- and observer-masked, 2-arm parallel group study.
Gender:
ALL
Ages:
Between 6 years and 8 years
Trial Updated:
12/18/2024
Locations: Omega Vision Center, Longwood, Florida
Conditions: Myopia, Juvenile Myopia, Myopia Progression
Study of the CHK1 Inhibitor BBI-355, an EcDNA-directed Therapy (ecDTx), in Subjects with Tumors with Oncogene Amplifications
Recruiting
BBI-355 is an oral, potent, selective checkpoint kinase 1 (or CHK1) small molecule inhibitor in development as an ecDNA (extrachromosomal DNA) directed therapy (ecDTx). This is a first-in-human, open-label, 3-part, Phase 1/2 study to determine the safety profile and identify the maximum tolerated dose and recommended Phase 2 dose of BBI-355 administered as a single agent or in combination with select therapies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/18/2024
Locations: Florida Cancer Specialists, Lake Mary, Florida
Conditions: Non-small Cell Lung Cancer, Non-Small Cell Lung Adenocarcinoma, Non-Small Cell Squamous Lung Cancer, Head and Neck Squamous Cell Carcinoma, Esophageal Cancer, Gastric Cancer, Breast Cancer, Bladder Cancer, Ovarian Cancer, Endometrial Cancer, Liposarcoma
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
Recruiting
This is a Phase 3,multicenter, randomized, open-label, blinded endpoint evaluation study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/18/2024
Locations: University of Miami Health, Miami, Florida
Conditions: Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism